Alys Jones

发表

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

O. Delpuech, S. Green, Á. Avivar-Valderas, 2016, Molecular Cancer Therapeutics.

A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer.

I. Judson, J. Hardy, S. Ashley, 1991, British Journal of Cancer.